4,4-二甲氧基-3-甲基-丁-2-酮 | 36075-03-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 4,4-二甲氧基-3-甲基-丁-2-酮
• 英文名称: 4,4-dimethoxy-3-methylbutan-2-one
• 英文别名: 4,4-dimethoxy-3-methyl-butan-2-one；2-methyl-3-oxo-butyraldehyde dimethyl acetal；2-Methyl-3-oxo-butyraldehyd-dimethylacetal；4,4-Dimethoxy-3-methyl-butan-2-on
• CAS: 36075-03-3
• 化学式: C₇H₁₄O₃
• 分子量: 146.186
• InChiKey: PPYDDVVHUXDXNZ-UHFFFAOYSA-N

物化性质

• 沸点：
  68-73 °C(Press: 8 Torr)
• 密度：
  0.945±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  4,4-二甲氧基-3-甲基-丁-2-酮 在 lithium hexamethyldisilazane 、 三氯氧磷 作用下， 以 1,2-二氯乙烷 为溶剂， 反应 9.17h， 生成 Methyl 5-formyl-3,4-dimethylfuran-2-carboxylate
  参考文献：
  名称：

  Synthesis and Characterization of All-Alkyl-Substituted Mono-, Di-, and Trioxosapphyrins

  摘要：

  The synthesis and characterization of the following heterosapphyrins is presented: 3,7,18,22-tetraethyl-2,8,12,13,17,23-hexamethyl-27-oxasapphyrin (5), 3,8,12,13,17,22-hexaethyl-2,7,18,23-tetramethyl-15,29-dioxasapphyrin (6), and 3,7,18,22-tetraethyl-2,8,12,13,17,23-hexamethyl-15,27,29-trioxasapphyrin (7). These macrocycles were synthesized from the hitherto unknown precursors methyl 3,4-dimethylfuran-2-carboxylate (11) and methyl 4-ethyl-3-methylfuran-2-carboxylate (12). Single-crystal X-ray diffraction structures of the bis(hydrochloric acid) salt (5a) and the bis(trifluoroacetic acid) salt (5b) of 5 and of the bis(hydrochloric acid) salt (6a) of 6 were obtained. These structures are compared to those of the parent all-aza sapphyrin 4. In this context, we report the first solid-state structural analysis of a trifluoroacetic acid salt of sapphyrin (4b). Crystals of 5a are triclinic, space group P (1) over bar in a cell of the dimensions a = 11.9686(13) Angstrom, b = 12.790(2) Angstrom, c = 16.236(2) Angstrom, alpha = 80.924(10)degrees, beta = 88.845(9)degrees, gamma = 80.481(10)degrees, V = 2420.5(5) Angstrom(3), F(000) = 1036, rho = 1.38 g cm(3) with Z = 2. Crystals of 5b are monoclinic, space group P2(1)/c, in a cell of the dimensions a = 9.590(1) Angstrom, b = 33.911(3) Angstrom, c = 13.200(1) Angstrom, beta = 94.931(6)degrees, V = 4276.8(6) Angstrom(3), F(000)= 1904, rho = 1.42 g cm(3), with Z = 4. Crystals of 6a are triclinic, space group P (1) over bar, in a cell of the dimensions a = 12.827(3) Angstrom, b = 13.116(3) Angstrom, c = 17.202(7) Angstrom, alpha = 82.89(2)degrees, beta = 82.14(2)degrees, gamma = 80.22(1)degrees, V = 2810(2) Angstrom(3), F(000) = 1184, rho = 136 g cm(3), with Z = 2. Crystals of 4b are triclinic, space group P (1) over bar, in a cell of the dimensions a = 11.431(3) Angstrom, b = 11.563(2) Angstrom, c = 16.367(4) Angstrom, alpha = 88.07(2)degrees, beta = 75.25(2)degrees, gamma = 86.50(2), V = 2087.8(9) Angstrom(3), F(000)= 872, rho = 1.32, with Z = 2. The monooxasapphyrin salt 5a displays a structure very similar to that of the parent all-azasapphyrin (4a) in that one chloride anion is bound 1.936 Angstrom above and one chloride anion 1.814 Angstrom below the plane of the macrocycle. These distances are 1.774 and 1.877 Angstrom, respectively, for 4a. Almost the same behavior is found for 5b. Here, the carboxylate anions are bound 1.085 Angstrom above and 1.870 Angstrom below the plane of the macrocycle. These distances are 1.305 and 1.444 Angstrom, respectively, for 4b. Completely different behavior is observed in the case of 6a. In this instance, only one chloride anion is bound directly with a distance of 1.685 Angstrom above the plane of the macrocycle, while the other chloride anion is well removed from the dioxasapphyrin and solvated by four chloroform molecules.

  DOI：

  10.1021/jo9715736
• 作为产物：
  描述：

  2-甲基-3-氧代丁酸甲酯 生成 4,4-二甲氧基-3-甲基-丁-2-酮
  参考文献：
  名称：

  MORIZUR, J. P.;MARTIGNY, I.;GERIBALDI, S.;TORTAJADA, J., SPECTA 2000, 18,(1990) N50, C. 12

  摘要：

  DOI：

文献信息

• Reactivite des derives de cyclopropylidene-3 propyle-I
  作者：M. Bertrand、G. Leandri、A. Meou

  DOI：10.1016/s0040-4020(01)98934-3

  日期：1981.1

  β-cyclopropylidenic alcohols has been synthesized through the following sequence: (i) Wittig condensation between cyclopropylidenetriphenylphosphorane with appropriate monoprotected 1,3-dicarbonyl compounds; (ii) smooth hydrolysis of acetals (after a necessary transacetalization step) and ketals thus formed; (iii) LAH reduction of aldehydes and ketones (yielding primary and secondary alcohols respectively)

  通过以下顺序合成了一系列的β-环亚丙基醇：（i）在环亚丙基三苯基苯基膦与适当的单保护的1，3-二羰基化合物之间的维蒂希缩合；（ii）缩醛的平滑水解（在必要的反缩醛化步骤之后），从而形成缩酮；（iii）LAH还原醛和酮（分别产生伯醇和仲醇）或用甲基锂处理酮（产生叔醇）。
• Construction of the basic skeleton of ophiobolin A and variecolin
  作者：Ke Li、Cheng Wang、Gang Yin、Shuanhu Gao

  DOI：10.1039/c3ob41693c

  日期：——

  Ophiobolin and variecolin type sesterterpenoids belong to cyclooctane-containing natural products. Both sesterterpenoids have challenging structures and appealing biological activities. We envisioned that a key tandem ring closing metathesis of dienynes could provide the basic skeleton of ophiobolin A and variecolin. We report herein the detailed reactivities of the dienynes which furnished the 5-8-5

  麦竹叶林和水松木类型的酯类萜类化合物属于含环辛烷的天然产物。两种酯类萜都具有挑战性的结构和有吸引力的生物活性。我们设想，关键的串联环闭合二烯的复分解可以提供ophiobolin A和variecolin的基本骨架。我们在此报告了有效地提供5-8-5和5-8-6-5环的二烯的详细反应性。
• FE(III) COMPLEX COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF IRON DEFICIENCY SYMPTOMS AND IRON DEFICIENCY ANEMIAS
  申请人：Bark Thomas

  公开号：US20140162994A1

  公开（公告）日：2014-06-12

  The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

  该发明涉及铁（III）配合物和包括它们的药物组合物，用作药物，特别是用于治疗和/或预防缺铁症状和缺铁性贫血。
• Total Synthesis of Cyanthiwigins A, C, G, and H
  作者：Cheng Wang、Dan Wang、Shuanhu Gao

  DOI：10.1021/ol4019425

  日期：2013.9.6

  The first total synthesis of cyanthiwigins A, C, H and concise synthesis of cyanthiwigin G was achieved from a common intermediate. A modified formal [4 + 2] cycloaddition was developed to construct the key cis-hydrindanone (A–B). Stereospecific 1,4-addition, alkylation, and ring-closing metathesis were used to build the tricarbocyclic ring system (A–B–C). Various site-selective oxidations were applied

  氰基维他命A，C，H的第一个全合成和氰基维他命G的简明合成是从一个常见的中间体完成的。改良的正式[4 + 2]环加成反应被开发出来，以构建关键的顺式-氢化丹酮（AB）。立体定向的1，4-加成，烷基化和闭环复分解用于构建三碳环体系（A–B–C）。进行了多种位点选择性氧化，以产生不同的氰基维他命素所需的氧化态。
• Fe(III) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
  申请人：Bark Thomas

  公开号：US09422247B2

  公开（公告）日：2016-08-23

  The invention relates to iron(III) complex compounds and pharmaceutical compositions comprising them for the use as medicaments, in particular for the treatment and/or prophylaxis of iron deficiency symptoms and iron deficiency anemias.

  本发明涉及铁(III)配合物化合物和包含它们的药物组合物，用作药物，特别是用于治疗和/或预防铁缺乏症状和铁缺乏性贫血。